A randomised, double-blind, placebo controlled phase II study of ANAVEX 2-73 in patients with Rett Syndrome
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs ANAVEX 2-73 (Primary)
- Indications Rett syndrome
- Focus Therapeutic Use
- 07 Aug 2017 According to an Anavex Life Sciences media release, ANAVEX2-73 has been granted Orphan Drug Designation by the FDA.
- 19 Jan 2017 According to an Anavex Life Sciences media release, this study is expected to initiate in 2017.
- 20 May 2016 New trial record